Recognition and management of platelet-refractory bleeding in patients with glanzmann’s thrombasthenia and other severe platelet function disorders

Meera Chitlur, Madhvi Rajpurkar, Michael Recht, Michael D. Tarantino, Donald L. Yee, David L. Cooper, Sriya Gunawardena

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Patients with rare qualitative platelet disorders or platelet function disorders (PFDs) may present to the hospital physician with severe bleeding episodes or excessive surgical bleeding. Although standard treatment consists of platelet transfusions, repeated transfusions may result in the development of antiplatelet antibodies (APA) or clinical refractoriness, rendering further platelet therapy ineffective. In such settings, an approved treatment option for patients with Glanzmann’s thrombasthenia (GT), one of the well-known rare PFDs, is recombinant activated coagulation factor VII (rFVIIa). Data regarding the efficacy of rFVIIa in patients with GT and platelet refractoriness are available from a large patient registry, an international survey, and multiple case reports and demonstrate efficacy in patients with and without refractoriness or APA. This article reviews the rFVIIa clinical data in patients with GT and platelet refractoriness and discusses clinical implications relevant to the hospital-based physician. Because uncontrolled bleeding can be life-threatening, hospital physicians should be alert to the signs of platelet refractoriness, be able to recognize continued internal or external bleeding, and know how to adapt treatment regimens for the effective management of bleeding. The management of patients who receive rFVIIa should occur in consultation with a hematologist with experience in PFDs, and patients with suspected platelet refractoriness should be referred to such a hematologist as early as possible. A critical unmet need is the development of a definition of an adequate response to platelet transfusion, which would facilitate early recognition of platelet refractoriness in patients with PFDs who exhibit a normal platelet count.

Original languageEnglish (US)
Pages (from-to)95-99
Number of pages5
JournalInternational Journal of General Medicine
Volume10
DOIs
StatePublished - Apr 3 2017

Fingerprint

Thrombasthenia
Blood Platelets
Hemorrhage
Platelet Transfusion
Physicians
Factor VIIa
Factor VII
Antibodies
Therapeutics
Platelet Count
Registries

Keywords

  • Alloantibodies
  • Antiplatelet antibodies
  • Bleeding management
  • Glanzmann’s thrombasthenia
  • Platelet function disorder
  • Platelet refractoriness

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Recognition and management of platelet-refractory bleeding in patients with glanzmann’s thrombasthenia and other severe platelet function disorders. / Chitlur, Meera; Rajpurkar, Madhvi; Recht, Michael; Tarantino, Michael D.; Yee, Donald L.; Cooper, David L.; Gunawardena, Sriya.

In: International Journal of General Medicine, Vol. 10, 03.04.2017, p. 95-99.

Research output: Contribution to journalArticle

Chitlur, Meera ; Rajpurkar, Madhvi ; Recht, Michael ; Tarantino, Michael D. ; Yee, Donald L. ; Cooper, David L. ; Gunawardena, Sriya. / Recognition and management of platelet-refractory bleeding in patients with glanzmann’s thrombasthenia and other severe platelet function disorders. In: International Journal of General Medicine. 2017 ; Vol. 10. pp. 95-99.
@article{d2c64ba40b1f4d9382f5ac594dd6913c,
title = "Recognition and management of platelet-refractory bleeding in patients with glanzmann’s thrombasthenia and other severe platelet function disorders",
abstract = "Patients with rare qualitative platelet disorders or platelet function disorders (PFDs) may present to the hospital physician with severe bleeding episodes or excessive surgical bleeding. Although standard treatment consists of platelet transfusions, repeated transfusions may result in the development of antiplatelet antibodies (APA) or clinical refractoriness, rendering further platelet therapy ineffective. In such settings, an approved treatment option for patients with Glanzmann’s thrombasthenia (GT), one of the well-known rare PFDs, is recombinant activated coagulation factor VII (rFVIIa). Data regarding the efficacy of rFVIIa in patients with GT and platelet refractoriness are available from a large patient registry, an international survey, and multiple case reports and demonstrate efficacy in patients with and without refractoriness or APA. This article reviews the rFVIIa clinical data in patients with GT and platelet refractoriness and discusses clinical implications relevant to the hospital-based physician. Because uncontrolled bleeding can be life-threatening, hospital physicians should be alert to the signs of platelet refractoriness, be able to recognize continued internal or external bleeding, and know how to adapt treatment regimens for the effective management of bleeding. The management of patients who receive rFVIIa should occur in consultation with a hematologist with experience in PFDs, and patients with suspected platelet refractoriness should be referred to such a hematologist as early as possible. A critical unmet need is the development of a definition of an adequate response to platelet transfusion, which would facilitate early recognition of platelet refractoriness in patients with PFDs who exhibit a normal platelet count.",
keywords = "Alloantibodies, Antiplatelet antibodies, Bleeding management, Glanzmann’s thrombasthenia, Platelet function disorder, Platelet refractoriness",
author = "Meera Chitlur and Madhvi Rajpurkar and Michael Recht and Tarantino, {Michael D.} and Yee, {Donald L.} and Cooper, {David L.} and Sriya Gunawardena",
year = "2017",
month = "4",
day = "3",
doi = "10.2147/IJGM.S128953",
language = "English (US)",
volume = "10",
pages = "95--99",
journal = "International Journal of General Medicine",
issn = "1178-7074",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Recognition and management of platelet-refractory bleeding in patients with glanzmann’s thrombasthenia and other severe platelet function disorders

AU - Chitlur, Meera

AU - Rajpurkar, Madhvi

AU - Recht, Michael

AU - Tarantino, Michael D.

AU - Yee, Donald L.

AU - Cooper, David L.

AU - Gunawardena, Sriya

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Patients with rare qualitative platelet disorders or platelet function disorders (PFDs) may present to the hospital physician with severe bleeding episodes or excessive surgical bleeding. Although standard treatment consists of platelet transfusions, repeated transfusions may result in the development of antiplatelet antibodies (APA) or clinical refractoriness, rendering further platelet therapy ineffective. In such settings, an approved treatment option for patients with Glanzmann’s thrombasthenia (GT), one of the well-known rare PFDs, is recombinant activated coagulation factor VII (rFVIIa). Data regarding the efficacy of rFVIIa in patients with GT and platelet refractoriness are available from a large patient registry, an international survey, and multiple case reports and demonstrate efficacy in patients with and without refractoriness or APA. This article reviews the rFVIIa clinical data in patients with GT and platelet refractoriness and discusses clinical implications relevant to the hospital-based physician. Because uncontrolled bleeding can be life-threatening, hospital physicians should be alert to the signs of platelet refractoriness, be able to recognize continued internal or external bleeding, and know how to adapt treatment regimens for the effective management of bleeding. The management of patients who receive rFVIIa should occur in consultation with a hematologist with experience in PFDs, and patients with suspected platelet refractoriness should be referred to such a hematologist as early as possible. A critical unmet need is the development of a definition of an adequate response to platelet transfusion, which would facilitate early recognition of platelet refractoriness in patients with PFDs who exhibit a normal platelet count.

AB - Patients with rare qualitative platelet disorders or platelet function disorders (PFDs) may present to the hospital physician with severe bleeding episodes or excessive surgical bleeding. Although standard treatment consists of platelet transfusions, repeated transfusions may result in the development of antiplatelet antibodies (APA) or clinical refractoriness, rendering further platelet therapy ineffective. In such settings, an approved treatment option for patients with Glanzmann’s thrombasthenia (GT), one of the well-known rare PFDs, is recombinant activated coagulation factor VII (rFVIIa). Data regarding the efficacy of rFVIIa in patients with GT and platelet refractoriness are available from a large patient registry, an international survey, and multiple case reports and demonstrate efficacy in patients with and without refractoriness or APA. This article reviews the rFVIIa clinical data in patients with GT and platelet refractoriness and discusses clinical implications relevant to the hospital-based physician. Because uncontrolled bleeding can be life-threatening, hospital physicians should be alert to the signs of platelet refractoriness, be able to recognize continued internal or external bleeding, and know how to adapt treatment regimens for the effective management of bleeding. The management of patients who receive rFVIIa should occur in consultation with a hematologist with experience in PFDs, and patients with suspected platelet refractoriness should be referred to such a hematologist as early as possible. A critical unmet need is the development of a definition of an adequate response to platelet transfusion, which would facilitate early recognition of platelet refractoriness in patients with PFDs who exhibit a normal platelet count.

KW - Alloantibodies

KW - Antiplatelet antibodies

KW - Bleeding management

KW - Glanzmann’s thrombasthenia

KW - Platelet function disorder

KW - Platelet refractoriness

UR - http://www.scopus.com/inward/record.url?scp=85017410807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017410807&partnerID=8YFLogxK

U2 - 10.2147/IJGM.S128953

DO - 10.2147/IJGM.S128953

M3 - Article

AN - SCOPUS:85017410807

VL - 10

SP - 95

EP - 99

JO - International Journal of General Medicine

JF - International Journal of General Medicine

SN - 1178-7074

ER -